Last reviewed · How we verify
medication review and deprescribing
At a glance
| Generic name | medication review and deprescribing |
|---|---|
| Sponsor | Regione del Veneto - AULSS n. 7 Pedemontana |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Population Health Approach to Optimizing Medications in Older Adults (NA)
- The Feasibility and Acceptability of a Collaborative Deprescribing Intervention to Reduce Anticholinergic Burden Among Hospitalised Older Patients (NA)
- Decreasing Polypharmacy in Older Adults With Curable Cancers Trial (PHASE1, PHASE2)
- Effects of Communication Training to Involve Older People in Decisions to DEPRESCRIBE Cardiometabolic Medication: a Cluster-randomized Trial in Primary Care (NA)
- Prescribing Outcomes of a GP-Targeted Deprescribing Educational Intervention: A Cluster Randomized Trial (NA)
- General Practitioner & Pharmacist Support for Discontinuing Long-term Antidepressants in Clinically Stable Patients (NA)
- Decreasing Harms and Improving Child Health (NA)
- Reduction of Low-value Prescribing Through Audit and Feedback (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: